Waikato Follow-up Study of People Admitted to Hospital with Chronic Obstructive Pulmonary Disease

In patients with exacerbation of chronic obstructive pulmonary disease (COPD) who have abnormal cardiac biomarkers, compared to those who do not have abnormal cardiac biomarkers and those who do not receive ventilatory support, do the abnormalities of cardiac biomarkers normalise when the patients are in stable COPD, do they reflect underlying abnormal cardiac function and do they have higher morbidity and mortality rate?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12612000548831

Acronym

BREATHE

Enrollment

176

Registered

2012-05-23

Start date

2012-08-06

Completion date

2013-07-25

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

COPD is very common and carries significant health and socioeconomic burden. Blood markers of impaired heart function are found to be raised in some patients with chronic obstructive pulmonary disease (COPD). This study is looking at the abnormality in the blood levels of these markers in COPD exacerbations and during stable period, to see if they are related to impaired heart function and the factors that might contribute to the abnormality. Heart function will be assessed by MRI scan of the heart. Those having acute severe worsening of their disease will require assisted breathing with a mask attached to a ventilator, named non-invasive ventilator (NIV), which is also in heart failure to reduce the work load of the heart. This study is also trying to find out if the level of these blood markers changes after NIV. This would suggest that there is an underlying impairment in heart function in patients with COPD which is not normally looked for. The outcome of this study will improve the treatment of COPD.

Interventions

In patients with exacerbation of COPD, the levels of cardiac biomarkers will be measured during hospitalisation, before and after non-invasive ventilation (in those who receive non-invasive ventilation) and during 30-day follow up. Those with abnormal cardiac biomarkers will have cardiac functional assessment to see if they have any correlation. They will also be followed up for a year for morbidity and mortality. We also compared levels of cardiac biomarkers in patients who received nebulised b

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Physician diagnosis of COPD. Fixed airflow obstruction (FEV1/FVC <70% and FEV1<80% of predicted) at presentation, in the last 6 months or at 30-day follow up. Over 40 years of age. At least 10pack years smoking history. Acute exacerbation of COPD as defined by dyspnoea, cough or sputum purulence severe enough to warrant hospital admission, respiratory failure or change in mental status due to COPD. In the patients receiving non-invasive ventilation, arterial blood gas indices of hypercapnic respiratory failure.

Exclusion criteria

Respiratory physician diagnosis of interstitial lung disease or bronchiectasis. Radiological diagnosis of pneumonia. Known diagnosis of clinically significant valvular heart disease. Known diagnosis of other terminal illness with prognosis less than 2 years. Inability to perform spirometry. Patient refusal to participate in the study or unable to give informed consent. Likely to leave Waikato region or become uncontactable during follow-up period.

Outcome results